These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
747 related articles for article (PubMed ID: 25991002)
1. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002 [TBL] [Abstract][Full Text] [Related]
2. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634 [TBL] [Abstract][Full Text] [Related]
3. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. Vassilakopoulou M; Togun T; Dafni U; Cheng H; Bordeaux J; Neumeister VM; Bobos M; Pentheroudakis G; Skarlos DV; Pectasides D; Kotoula V; Fountzilas G; Rimm DL; Psyrri A PLoS One; 2014; 9(6):e99131. PubMed ID: 24968015 [TBL] [Abstract][Full Text] [Related]
4. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558 [TBL] [Abstract][Full Text] [Related]
5. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139 [TBL] [Abstract][Full Text] [Related]
6. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A; Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181 [TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Murthy RK; Varma A; Mishra P; Hess KR; Young E; Murray JL; Koenig KH; Moulder SL; Melhem-Bertrandt A; Giordano SH; Booser D; Valero V; Hortobagyi GN; Esteva FJ Cancer; 2014 Jul; 120(13):1932-8. PubMed ID: 24677057 [TBL] [Abstract][Full Text] [Related]
8. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M J BUON; 2015; 20(3):714-22. PubMed ID: 26214622 [TBL] [Abstract][Full Text] [Related]
9. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523 [TBL] [Abstract][Full Text] [Related]
10. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807 [TBL] [Abstract][Full Text] [Related]
11. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054 [TBL] [Abstract][Full Text] [Related]
12. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S J BUON; 2013; 18(1):44-50. PubMed ID: 23613387 [TBL] [Abstract][Full Text] [Related]
13. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861 [TBL] [Abstract][Full Text] [Related]
14. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260 [TBL] [Abstract][Full Text] [Related]
15. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Tan QX; Qin QH; Yang WP; Mo QG; Wei CY Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769 [TBL] [Abstract][Full Text] [Related]
17. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Knutson KL; Clynes R; Shreeder B; Yeramian P; Kemp KP; Ballman K; Tenner KS; Erskine CL; Norton N; Northfelt D; Tan W; Calfa C; Pegram M; Mittendorf EA; Perez EA Cancer Res; 2016 Jul; 76(13):3702-10. PubMed ID: 27197192 [TBL] [Abstract][Full Text] [Related]
18. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]